Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms

Br J Surg. 2001 Nov;88(11):1472-5. doi: 10.1046/j.0007-1323.2001.01911.x.

Abstract

Background: The cysteine protease inhibitor cystatin C may play a role in the development and progression of abdominal aortic aneurysms (AAAs).

Methods: From a mass screening trial of men aged 65-73 years, 151 small AAAs were followed for a mean of 2.9 years. Of these patients, 142 had serum samples taken to determine the levels of cystatin C, creatinine and C-reactive protein (CRP).

Results: Serum cystatin C concentration correlated negatively with AAA size (r = - 0.22 (95 per cent confidence interval (c.i.) - 0.59 to - 0.02)) and annual expansion rate (r = - 0.24 (95 per cent c.i. - 0.75 to - 0.05)), persisting after adjustment for renal function, smoking, diastolic blood pressure, CRP, age and AAA size. Creatinine clearance and CRP did not correlate with size or expansion rate. Thirty-one AAAs had expanded to over 50 mm, when operation was recommended. The serum level of cystatin C was a significant predictor of this occurrence, with a sensitivity and specificity of 61 and 57 per cent respectively. However, initial AAA size had the optimal sensitivity and specificity (both 81 per cent) in this regard.

Conclusion: Deficiency of cystatin C was associated with increased aneurysm size and expansion rate, possibly due to lack of inhibition of cysteine proteases.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aortic Aneurysm, Abdominal / blood*
  • Aortic Aneurysm, Abdominal / pathology
  • Aortic Aneurysm, Abdominal / physiopathology
  • Biomarkers / blood
  • Blood Pressure
  • Cystatin C
  • Cystatins / blood
  • Cystatins / deficiency*
  • Disease Progression
  • Humans
  • Male
  • Sensitivity and Specificity

Substances

  • Biomarkers
  • CST3 protein, human
  • Cystatin C
  • Cystatins